

Compound of Formula I Cmax (ng / ml)
8000
6000
4000
2000
0
fasted
fed
fasted
fed
fasted
fed
fasted
fed
fasted
fed
fasted
fed
200 mg BID
600 mg BID
900 mg BID
1200 mg BID
no MTX
w MTX

FIG. 1



Compound of Formula I 800 mg bid fasting
Sample size: 10-40/arm
CLL
FL
DLBCL
MCL
LPL, SLL, MZL
Results Cross Futility Boundary
Yes
No
Consider stopping accrual in that malignancy
Continue accrual to a maximum of 40 subjects
Continue accrual to a maximum of 40 total subjects

FIG. 2



Still on Study
Off Study
CLL
iNHL (a)
MCL (b)
DLBCL (c)
Safety Data Set: Subjects receiving first dose at least 28 days prior to the data cutoff date (n=78)
Efficacy Data Set: Subjects receiving first dose at least 56 days prior to the data cutoff date (CLL n=29, NHL n=28)
Subject Number (N=43)
Subject Number (N=47)
0
28
56
84
112
140
168

FIG. 3




Very high risk (w 17p deletion and/or TP53 mutation)
High risk (w NOTCH1 and/or SF3B1 mutation and/or 11q deletion)
Low risk (none of the above deletion or mutation)
Best Percentage Change in SPD at Week 8 and 16
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
*
*
*
*
*
69.0% nodal response rate
*Progressive disease overall assessment

FIG. 4



*Progressive disease overall assessment

FIG. 5



% Change in SPD from Baseline, Mean (± SE)
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
Percent Change in Lymph Node Size
N=10
N=28
Absolute Lymphocyte Count
ALC, Mean (+/- SE), x10³/µL
100
90
80
70
60
50
40
30
20
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Weeks from First Dose

FIG. 6





6 Subjects Re-challenged
• 4 on study at 600 mg BID
• 1 withdrew consent
• 1 Gr 2 rash → went off study
ALT (U/L)
1800
1600
1400
1200
1000
800
600
400
200
0
1
8
15
22
29
36
43
50
57
64
71
78
85
92
99
106
113
Day from First Dose

FIG. 7



*Mean (± SE) of pSyk, pBlnk and pBtk Over Time

FIG. 8



*Mean (± SE) of CCL3, CCL4, CCL22, and TNF-α Over Time

FIG. 9